Press release content from PR Newswire. The AP news staff was not involved in its creation. Medicines360, MSI Reproductive Choices and MSK Announce Launch of Avibela® Hormonal Intrauterine Device in Kenya August 2, 2021 GMT None SAN FRANCISCO and LONDON and NAIROBI, Kenya, Aug. 2, 2021 /PRNewswire/ -- Medicines360, MSI Reproductive Choices (MSI) and Marie Stopes Kenya (MSK) today announced the launch of AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg in Kenya. This is the third launch of Medicines360′s hormonal intrauterine device (IUD) in Africa, following Madagascar and Zambia. “Through our partnership with MSI and MSK, women in Kenya will gain increased access to an affordable and effective long-acting reversible contraceptive. We are committed to closing gaps in women’s health, and AVIBELA will help us reach a population of women who don’t have access to the full range of contraceptive methods,” said Tina Raine-Bennett, MD, MPH, FACOG, Chief Executive Officer, Medicines360. “Research has shown that making more methods of contraception widely available in a country better meets the needs of women and couples, resulting in an increase in overall contraceptive use.”